Proportion of participants with IOP ≤ 21 mmHg, with or without ocular hypotensive medications, 4 to 6 weeks · people with neovascular glaucoma
Anti‐VEGF may leads to higher proportion of participants with IOP ≤ 21 mmHg, with or without… compared with no anti‐VEGF (low certainty).
1 finding from 1 review
Mean IOP ( · people with neovascular glaucoma
It is very uncertain whether anti‐VEGF changes mean IOP, 4 to 6 weeks compared with no anti‐VEGF (very low certainty).
1 finding from 1 review
Visual acuity · people with neovascular glaucoma
It is very uncertain whether anti‐VEGF changes proportion of participants with improvement in visual acuity of 2… compared with no anti‐VEGF (very low certainty).
1 finding from 1 review
Proportion of participants with complete regression of new iris vessels, 4 to 6 weeks · people with neovascular glaucoma
Anti‐VEGF may leads to higher proportion of participants with complete regression of new iris… compared with no anti‐VEGF (low certainty).
1 finding from 1 review
Proportion of participants with relief of pain and resolution of redness, 1 year · people with neovascular glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events assessed in various ways, up to 24 months · people with neovascular glaucoma
1 finding from 1 review
no estimate extracted
6 participants
GRADE not reported
Number of anti‐VEGF injections · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Gain of 15 letters or more of visual acuity at 6 months · macular oedema secondary to branch retinal vein occlusion
Anti‐VEGF probably leads to higher gain of 15 letters or more of visual acuity at 6 months compared with sham (moderate certainty).
1 finding from 1 review
QoL · people with BRVO
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BCVA: gain of 15 or more ETDRS letters · people with BRVO
Anti‐VEGF leads to higher gain of 15 letters or more of visual acuity compared with steroid (high certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with BRVO
1 finding from 1 review
Central retinal thickness μm (CRT) change at 1 year The aim of treatment is to reduce central retinal thickness so thinner is better. · people with BRVO
1 finding from 1 review
Adverse outcomes at any time point · people with BRVO
Anti‐VEGF probably leads to lower adverse outcomes at any time point compared with steroid (moderate certainty).
1 finding from 1 review
QoL · people with BRVO
1 finding from 1 review
Visual acuity · macular oedema secondary to branch retinal vein occlusion
1 finding from 1 review
Mean central retinal thickness (CRT) change at 6 months in microns (lower value is better) · macular oedema secondary to branch retinal vein occlusion
1 finding from 1 review
Adverse outcomes at any time point · macular oedema secondary to branch retinal vein occlusion
It is very uncertain whether anti‐VEGF changes adverse outcomes at any time point compared with sham (very low certainty).
1 finding from 1 review
QoL · macular oedema secondary to branch retinal vein occlusion
1 finding from 1 review
BCVA: gain of 15 or more ETDRS letters · people with BRVO
Anti‐VEGF probably leads to higher gain of 15 letters or more of visual acuity compared with laser (moderate certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with BRVO
1 finding from 1 review